The estimated Net Worth of Elena Ridloff is at least $2.28 Milione dollars as of 29 April 2021. Ms. Ridloff owns over 3,245 units of Acadia Pharmaceuticals Inc stock worth over $184,781 and over the last 6 years she sold ACAD stock worth over $103,801. In addition, she makes $1,990,870 as Executive Vice President e Chief Financial Officer at Acadia Pharmaceuticals Inc.
Sign up
Ms. Ridloff ACAD stock SEC Form 4 insiders trading
Elena has made over 6 trades of the Acadia Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 3,245 units of ACAD stock worth $51,758 on 29 April 2021.
The largest trade she's ever made was exercising 36,000 units of Acadia Pharmaceuticals Inc stock on 9 December 2019 worth over $569,160. On average, Elena trades about 2,995 units every 25 days since 2019. As of 29 April 2021 she still owns at least 11,585 units of Acadia Pharmaceuticals Inc stock.
You can see the complete history of Ms. Ridloff stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Elena Ridloff biography
Elena H. Ridloff serves as Executive Vice President, Chief Financial Officer of the Company. She is our Executive Vice President, Chief Financial Officer. Ms. Ridloff was previously Senior Vice President, Investor Relations and Interim Chief Financial Officer and has been with our company since April 2018. Ms. Ridloff joined us from Alexion Pharmaceuticals, Inc., where she served as Executive Director, Investor Relations from April 2014 to January 2016 and Vice President, Investor Relations from January 2016 to March 2018, and served as a member of Alexion’s Operating Committee. While at Alexion, Ms. Ridloff was responsible for building and leading an investor relations function. Prior to joining Alexion, Ms. Ridloff served as the Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm providing strategic, financial and investor relations counsel to the life sciences industry, from January 2012 to April 2014. Ms. Ridloff also served as Managing Director at Maverick Capital, a hedge fund responsible for investments in the biotechnology, pharmaceutical, medical device and life science sectors, from July 2005 to January 2012. Ms. Ridloff earned her B.A. in history and sociology of science from the University of Pennsylvania, and is a Chartered Financial Analyst.
What is the salary of Elena Ridloff?
As the Executive Vice President e Chief Financial Officer of Acadia Pharmaceuticals Inc, the total compensation of Elena Ridloff at Acadia Pharmaceuticals Inc is $1,990,870. There are 3 executives at Acadia Pharmaceuticals Inc getting paid more, with Stephen Davis having the highest compensation of $7,631,250.
How old is Elena Ridloff?
Elena Ridloff is 40, she's been the Executive Vice President e Chief Financial Officer of Acadia Pharmaceuticals Inc since 2019. There are 15 older and no younger executives at Acadia Pharmaceuticals Inc. The oldest executive at Acadia Pharmaceuticals Inc is Edmund Harrigan, 67, who is the Independent Director.
What's Elena Ridloff's mailing address?
Elena's mailing address filed with the SEC is C/O KRONOS BIO, INC., 1300 SO. EL CAMINO REAL, SUITE 400, SAN MATEO, CA, 94402.
Insiders trading at Acadia Pharmaceuticals Inc
Over the last 20 years, insiders at Acadia Pharmaceuticals Inc have traded over $21,409,958 worth of Acadia Pharmaceuticals Inc stock and bought 29,279,665 units worth $647,484,672 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... e Carl L Gordon. On average, Acadia Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,248,934. The most recent stock trade was executed by Mark C. Schneyer on 16 August 2024, trading 9,733 units of ACAD stock currently worth $148,720.
What does Acadia Pharmaceuticals Inc do?
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies
What does Acadia Pharmaceuticals Inc's logo look like?
Complete history of Ms. Ridloff stock trades at Acadia Pharmaceuticals Inc, Kymera Therapeutics e Kronos Bio
Acadia Pharmaceuticals Inc executives and stock owners
Acadia Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Stephen Davis,
Director and Chief Executive Officer -
Srdjan Stankovic,
President -
Michael Yang,
Executive Vice President, Chief Commercial Officer -
Elena Ridloff,
Executive Vice President, Chief Financial Officer -
Austin Kim,
Executive Vice President, General Counsel, and Secretary -
Stephen R. Davis J.D.,
CEO & Director -
Dr. Srdjan R. Stankovic,
Pres -
Austin D. Kim,
Exec. VP, Gen. Counsel & Sec. -
Daniel Soland,
Independent Director -
James Daly,
Independent Director -
Edmund Harrigan,
Independent Director -
Stephen Biggar,
Independent Chairman of the Board -
Laura Brege,
Independent Director -
Julian Baker,
Independent Director -
Mark Johnson,
Vice President, Investor Relations -
Elizabeth Garofalo,
Director -
James Kihara,
Principal Accounting Officer -
Ponni Subbiah,
Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer -
Mark Schneyer,
Senior Vice President, Business Development and Chief Business Officer -
Stephanie Fagan,
Senior Vice President - Corporate Affairs, Chief Communications Officer -
Gudarz Davar,
Executive Vice President - Head of Research and Development -
Julie Fisher,
Sr. VP of Marketing & Commercial Strategy -
Dr. Kathie M. Bishop Ph.D.,
Sr. VP, Chief Scientific Officer & Head of Rare Disease -
Bob Mischler,
Sr. VP of Strategy & Technology Operations -
James K. Kihara,
VP, Corp. Controller & Principal Accounting Officer -
Brendan Teehan,
Exec. VP, COO & Head of Commercial -
Bros. Advisors Lpbaker Feli...,
-
Mary Ann Gray,
Director -
Terrence O Moore,
EVP, CHIEF COMMERCIAL OFFICER -
L.P.667, L.P.Baker Bros. Ad...,
-
Leslie L Iversen,
-
Bros. Advisors Lp667, L.P.B...,
-
Bros. Advisors Lp14159, L.P...,
-
Todd S. Young,
EVP AND CFO -
Roger Mills,
Executive VP, Development -
Uli Hacksell,
Chief Executive Officer -
Michael T Borer,
Director -
Thomas H Aasen,
VP, CFO, Sec. Treas. -
Lester J Ph D Kaplan,
Director -
Torsten Rasmussen,
Director -
Robert E Davis,
Exec. VP, Drug Discovery -
William Mc Dowall Wells,
-
Bros Advisors Llcbaker Feli...,
-
Bioscience Partners Iv Lpmr...,
-
Osch Martien Van,
Director -
Bioscience Partners Iv Lpob...,
-
Carl L Gordon,
Director -
Felixbaker Julianbaker Bros...,
-
Mark R Brann,
Pres., Chf. Scientific Officer -
Alan Walton,
Director -
Glenn Baity,
EVP AND GC -
Bo Ragnar Tolf,
VP Chm/Mng Dir ACADIA Phrm A/S -
Gordon M Binder,
Director -
Brian Lundstrom,
Sr. VP. Business Development -
John Joseph Kaiser,
VP, Strat. Mrkting & Com. Dev. -
Adora Ndu,
-
Brendan Teehan,
EVP, COO, HEAD OF COMMERCIAL -
Douglas J Williamson,
Executive VP, Research & Dev -
Bros. Advisors Lp667, L.P.B...,
-
Jennifer J Rhodes,
EVP, CHIEF LEGAL OFFICER, SEC -
Elizabeth H.Z. Thompson,
EVP, Head of Research & Dev